Document is current

Article History

Received: 15 August 2024

Revised: 20 September 2024

Accepted: 30 September 2024

First Online: 6 November 2024

Declarations

:

: EG-Y received grants/contracts from Amgen, Aslan, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, GSK, Incyte, Kyowa Kirin, Leo Pharma, Pfizer, RAPT, Sanofi, and UCB; received consulting fees from AbbVie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma Inc., AstraZeneca, Bristol Meyers Squibb, Boehringer Ingelheim, Cara Therapeutics, Centrexion Therapeutics Corporation, Concert, Connect Biopharm, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals Inc., Fairmount Funds Management LLC, FL2022-001 Inc., Galderma, Gate Bio, Google Ventures, GSK Immunology, Horizon Therapeutics USA Inc., Incyte, Inmagene, Janssen Biotech, Japan Tobacco, Jasper Therapeutics, Kyowa Kirin, Leo Pharma, Merck, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, NUMAB Therapeutics AG, OrbiMed Advisors LLC, OTSUKA, Pfizer, Pharmaxis Ltd, Pioneering Medicine VII Inc., Proteologix US Inc., RAPT, Regeneron Pharmaceuticals, RibonTherapeutics Inc., Sanofi, SATO, Schrödinger Inc., Sun Pharma Advanced Research Company, Teva Branded Pharmaceutical Products R&D Inc., and UCB; EE is an employee of Kyowa Kirin; HM is an employee of Kyowa Kirin; TA is an employee and stock holder of Kyowa Kirin; ADI received consulting fees from AbbVie, Arena, Benevolent AI, Eli Lilly, Leo Pharma, Novartis, Pfizer, Regeneron, and Sanofi; received payment/honoraria from AbbVie, Eli Lilly, Janssen, Leo Pharma, Regeneron, and Sanofi; has patents pending with J & J, and Regeneron; has leadership/fiduciary roles in International Eczema Council; MJC received research grants from Hyphens Pharma, J & J, Leo Pharma, L’Oréal, Perrigo (ACO Nordic), and Sanofi Genzyme; received consulting fees and payment/honoraria from, and participated in Data Safety Monitoring/Advisory Board for Hyphens Pharma, J & J, Leo Pharma, L’Oréal, Perrigo (ACO Nordic), Regeneron, and Sanofi Genzyme + Kymab (subsid); is a voluntary Medical Advisor for the National Eczema Society (UK); KK received research grants/contracts from AbbVie, Astellas Kyowa Kirin, Jansen Biotech, Maruho, P&G Japan, Taiho, Tanabe Mitsubishi, Toray and Torii; received consulting fees from Eli Lilly, Maruho, and Leo Pharma; received honoraria from Bristol Myers Squibb, Leo Pharma, Maruho, Sanofi, Taiho, and Torii; CC was an employee of Kyowa Kirin at the time the study was conducted; ES received grants/contracts from AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Eli Lilly, Incyte, Kymab, Kyowa Kirin, National Jewish Health, Leo Pharma, Pfizer, Regeneron, Sanofi, Target, and VeriSkin; received consulting fees from AbbVie, Advances in Cosmetic Medical Derm Hawaii LLC, Amgen, AOBiome LLC, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Boehringer Ingelheim USA Inc., Boston Consulting Group, Bristol Myers Squibb, Collective Acumen LLC, CorEvitas, Dermira, Eli Lilly, Evelo Biosciences, Evidera, ExcerptaMedica, FIDE, Forte Bio RX, Galderma, GSK, Gilead Sciences, Inc., Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, J & J, Kyowa Kirin Pharmaceutical Development, Leo Pharma, Medscape LLC, Merck, MauiDerm, MLG Operating, MJH holding, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Revolutionizing Atopic Dermatitis Inc., Roivant, Sanofi-Genzyme, Trevi Therapeutics, Valeant, Vindico Medical education, and WebMD; received payment/honoraria from AbbVie, Advances in Cosmetic Medical Derm Hawaii LLC, Amgen, AOBiome LLC, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Boehringer Ingelheim USA, Inc., Boston Consulting Group, Bristol Myers Squibb, Collective Acumen LLC, CorEvitas, Dermira, Eli Lilly, Evelo Biosciences, Evidera, ExcerptaMedica, FIDE, Forte Bio RX, Galderma, GSK, Gilead Sciences Inc., Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, J & J, Kyowa Kirin Pharmaceutical Development, Leo Pharma, Medscape LLC, Merck, MauiDerm, MLG Operating, MJH holding, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Revolutionizing Atopic Dermatitis Inc., Roivant, Sanofi-Genzyme, Trevi therapeutics, Valeant, Vindico Medical education, WebMD; received support for attending meetings/travel from FIDE, Maui Derm, Sanofi-Regeneron; participated in Data Safety Monitoring/Advisory Board for Arena, Eli Lilly, GSK, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Merck, Pfizer, Regeneron, Sanofi; and has leadership/fiduciary roles in AAD, International Society for Atopic Dermatitis, National Eczema Association, Sanofi Genzyme and Regeneron USA, and Harmonizing Outcome Measures in Eczema Working Group.

: The study protocol was approved by the Institutional Review Board or Independent Ethics Committee and regulatory health authorities in accordance with local regulations before study commencement. The study was conducted in full accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines. All patients provided written informed consent before participating in the trial.

: All patients provided written informed consent before participating in the trial.